Delphine C Malherbe, Jason Mendy, Lo Vang, Philip T Barnette, Jason Reed, Samir K Lakhashe, Joshua Owuor, Johannes S Gach, Alfred W Legasse, Michael K Axthelm, Celia C LaBranche, David Montefiori, Donald N Forthal, Byung Park, James M Wilson, James H McLinden, Jinhua Xiang, Jack T Stapleton, Jonah B Sacha, Barton F Haynes, Hua-Xin Liao, Ruth M Ruprecht, Jonathan Smith, Marc Gurwith, Nancy L Haigwood, Jeff Alexander
HIV vaccine development is focused on designing immunogens and delivery methods that elicit protective immunity. We evaluated a combination of adenovirus (Ad) vectors expressing HIV 1086.C (clade C) envelope glycoprotein (Env), SIV Gag p55, and human pegivirus GBV-C E2 glycoprotein. We compared replicating simian (SAd7) with nonreplicating human (Ad4) adenovirus-vectored vaccines paired with recombinant proteins in a novel prime-boost regimen in rhesus macaques, with the goal of eliciting protective immunity against SHIV challenge...
January 15, 2018: Journal of Virology